Trending News Today: Ripretinib Improves Progression-Free Survival in Stomach Cancer

Ripretinib, Deciphera Pharmaceuticals’ investigational treatment for stomach cancer, met the main goal of improving progression-free survival (PFS) in a late-stage study, Reuters reported. According to the article, the study evaluated ripretinib against placebo in 129 patients with advanced gastrointestinal stromal tumors. Overall, ripretinib demonstrated a median PFS rate of 6.3 months compared with 1 month in the placebo group, with a reduced risk of disease progression or death by 85%, the article reported.
 
A new study indicates that negative biases associated with irritable bowel syndrome (IBS) activity may lead to the development of depression in patients with the disease, MD Magazine reported. According to the article, the study examined the role of emotional processing biases in contributing to depression in 120 patients with IBD. Patients who had depression were more likely to be female, lacking in social support, had active disease, and were taking corticosteroids, but not tumor necrosis factor inhibitors, while exhibiting less positive emotional recognition bias, the article reported. 
 
A study published in the American Medical Association’s internal medicine journal found that 4 in 10 privately insured patients faced surprise medical bills after visiting in-network hospitals in 2016, The Hill reported. According to the article, the cost of a surprise emergency department-related bill increased from $220 in 2010 to $628 in 2016 and for inpatient admissions increased from $804 to $2040 over the same timeframe. From 2010, the number of emergency department visits and inpatient admissions that resulted in surprise bills increased by 10 and 16 percentage points, respectively, the article reported. 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.
Top news of the day from across the health care landscape.
Top news of the day from across the health care landscape.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$